Several clinical trials are investigating the safety and efficacy of combining bevacizumab (anti-VEGF) with atezolizumab (anti-PDL-1) in CRC at this moment (NCT02873195, NCT02291289, NCT02876224, NCT01633970) [103]. The gene discussed is CD274; the disease is colorectal carcinoma.